

Details of Revenue

(Billions of Yen)

	2017.3	2018.3	2019.3	2020.3	2021.3 (Forecast)
Sales of Major Products					
OPDIVO Intravenous Infusion	103.9	90.1	90.6	87.3	90.0
GLACTIV Tablets	29.4	27.4	26.9	26.1	25.0
FORXIGA Tablets	7.8	11.1	14.5	18.1	22.5
ORENCIA for Subcutaneous Injection	11.6	14.1	17.4	19.8	21.5
EMEND Capsules / PROEMEND for Intravenous Injection	9.9	9.9	10.6	10.7	7.0
RIVASTACH Patch	8.9	8.9	8.9	8.5	8.5
PARSABIV Intravenous Infusion	0.2	3.4	5.7	7.1	7.5
KYPROLIS for Intravenous Injection	2.0	5.5	4.9	6.0	6.5
ONOACT for Intravenous Infusion	5.7	5.6	4.6	4.9	6.0
OPALMON Tablets	17.0	14.4	10.4	8.3	5.0
ONON Capsules	6.8	5.5	4.4	3.5	3.0
RECALBON Tablets	11.3	10.9	7.3	4.7	2.0
Products to be newly launched	—	—	—	—	5.0
* Based on ex-manufacturer prices					
Breakdown of Revenue					
Revenue of goods and products	214.3	205.9	208.9	205.6	210.0
Royalty and other revenue	30.5	55.9	79.7	86.8	93.0
Sales Revenue by Region					
Japan	214.0	204.0	207.4	202.9	
Americas	27.3	52.5	72.3	81.5	
Asia	3.1	5.1	7.4	7.5	
Europe	0.4	0.2	1.6	0.5	